<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2028">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643444</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02650</org_study_id>
    <nct_id>NCT04643444</nct_id>
  </id_info>
  <brief_title>Police COVID-19 Serosurvey</brief_title>
  <acronym>PoliCOV</acronym>
  <official_title>Police Officer COVID-19 Seroprevalence Survey in the Canton of Bern, Switzerland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Interregionale Blutspende SRK Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to determine the immune status of the employees of the cantonal police&#xD;
      of Bern against SARS-CoV-2 over a period of 1 year, and to investigate the risk profile of&#xD;
      the study participants and their risk of SARS-CoV-2 exposure in their working and private&#xD;
      environments, as well as to evaluate the use of personal protective equipment at potential&#xD;
      exposure instances.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      i) To determine the extent of infection with seroprevalence data in the special population of&#xD;
      police officers of the canton Bern.&#xD;
&#xD;
      ii) To determine risk factors for infection by comparing the proportion of seropositivity&#xD;
      (infected versus noninfected individuals). The investigators hypothesize that police officers&#xD;
      with fieldwork activity will have a higher seroprevalence than will office and administration&#xD;
      personnel. The investigators hypothesize that working in the city of Bern will be associated&#xD;
      with a higher seroprevalence than will working in other geographic areas of the canton (i.e.&#xD;
      rural area).&#xD;
&#xD;
      iii) To monitor COVID-19 antibody titres and neutralizing capacity over time and to associate&#xD;
      them with reinfection rates and infection-free intervals in police officers after accidental&#xD;
      contact with a proven COVID-19 case. The investigators hypothesize that in seropositive&#xD;
      individuals, there will be a decreasing dynamic of antibody titres over the one-year study&#xD;
      period, and hence, a decrease of neutralizing capacity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprevalence</measure>
    <time_frame>One year</time_frame>
    <description>The variable of primary interest is COVID-19 seropositivity. This variable is measured at five time points over the one-year study period. The following baseline factors may have an influence on the primary endpoint and will be obtained: (i) pre-existing comorbidities, (ii) rural versus city distribution of working place, and (iii) office work versus field work.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk profile assessment</measure>
    <time_frame>One year</time_frame>
    <description>The investigators will assess the proportion of symptomatic and asymptomatic cases among seropositive participants. The investigators will calculate the attack rate in different subgroup. These include (i) study participants with health-related risk factors (age&gt;50 and age&gt;60 years, diabetes, arterial hypertension, cardiovascular disease, chronic pulmonary disease, immune-compromised status due to host diseases, medical treatment, cancer, obesity), (ii) activity-related subgroups (i.e. fieldwork vs office activity), (iii) geography-related subgroups (i.e. city vs rural areas). In follow-up visits, the antibody titers (i.e. dynamic) and the neutralization capacity will be assessed. Thereby, the investigators will determine the change in serum levels of SARS-CoV-2 antibodies over time in seropositive participants.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Volunteers</condition>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Testing for the presence of SARS-CoV-2 antibodies</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online Questionnaire</intervention_name>
    <description>Questions on working place, risk profiles and PPE</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Employees of the cantonal police of Bern, Switzerland&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Police officers of the cantonal police of Bern volunteering to participate in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal or inability to give informed consent or contraindication to venepuncture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parham Sendi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parham Sendi, MD</last_name>
    <phone>+41316326986</phone>
    <email>parham.sendi@ifik.unibe.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Bern, Institute for Infectious Diseases</name>
      <address>
        <city>Bern</city>
        <state>BE</state>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parham Sendi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Seroprevalence</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

